Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CymaBay Therapeutics Inc.

    NASDAQ: CBAY · Real-Time Price · USD
    32.48
    0.01 (0.03%)
    At close: Mar 21, 2024, 8:00 PM

    CymaBay Therapeutics Statistics

    Share Statistics

    CymaBay Therapeutics has 114.78M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 114.78M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 171

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -23.81 and the forward PE ratio is null. CymaBay Therapeutics's PEG ratio is 0.89.

    PE Ratio

    n/a
    		 -23.81

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 80.73

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 8.58

    P/FCF Ratio

    n/a
    		 -34.37

    PEG Ratio

    n/a
    		 0.89
    Financial Ratio History

    Enterprise Valuation

    CymaBay Therapeutics has an Enterprise Value (EV) of 2.42B.

    EV / Sales

    n/a
    		 77.77

    EV / EBITDA

    n/a
    		 -28.18

    EV / EBIT

    n/a
    		 -33.32

    EV / FCF

    n/a
    		 -33.11

    Financial Position

    The company has a current ratio of 10.96, with a Debt / Equity ratio of 0.39.

    Current Ratio

    n/a
    		 10.96

    Quick Ratio

    n/a
    		 10.96

    Debt / Equity

    n/a
    		 0.39

    Debt / EBITDA

    n/a
    		 -1.34

    Debt / FCF

    n/a
    		 -1.57

    Interest Coverage

    n/a
    		 -5.37

    Financial Efficiency

    Return on Equity is -36.05% and Return on Invested Capital is -25%.

    Return on Equity

    n/a
    		 -36.05%

    Return on Assets

    n/a
    		 -24.24%

    Return on Invested Capital

    n/a
    		 -25%

    Revenue Per Employee

    n/a
    		 $307,653.47

    Profits Per Employee

    n/a
    		 $-1,043,267.33

    Employee Count

    n/a
    		 101

    Asset Turnover

    n/a
    		 0.07

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 0.32, so CymaBay Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.32

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 28.94

    200-Day Moving Average

    n/a
    		 18.65

    Relative Strength Index (RSI)

    n/a
    		 80.99

    Average Volume (20 Days)

    n/a
    		 3,944,615

    Income Statement

    In the last 12 months, CymaBay Therapeutics had revenue of 31.07M and earned -105.37M in profits. Earnings per share was -0.99.

    Revenue

    n/a
    		 31.07M

    Gross Profit

    n/a
    		 30.39M

    Operating Income

    n/a
    		 -101.68M

    Net Income

    n/a
    		 -105.37M

    EBITDA

    n/a
    		 -85.74M

    EBIT

    n/a
    		 -86.42M

    Earnings Per Share (EPS)

    n/a
    		 -0.99
    Full Income Statement

    Balance Sheet

    The company has 206.53M in cash and 114.49M in debt, giving a net cash position of 92.04M.

    Cash & Cash Equivalents

    n/a
    		 206.53M

    Total Debt

    n/a
    		 114.49M

    Net Cash

    n/a
    		 92.04M

    Retained Earnings

    n/a
    		 -978.23M

    Total Assets

    n/a
    		 434.69M

    Working Capital

    n/a
    		 366.96M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -72.53M and capital expenditures -445K, giving a free cash flow of -72.98M.

    Operating Cash Flow

    n/a
    		 -72.53M

    Capital Expenditures

    n/a
    		 -445K

    Free Cash Flow

    n/a
    		 -72.98M

    FCF Per Share

    n/a
    		 -0.69
    Full Cash Flow Statement

    Margins

    Gross margin is 97.81%, with operating and profit margins of -327.23% and -339.1%.

    Gross Margin

    n/a
    		 97.81%

    Operating Margin

    n/a
    		 -327.23%

    Pretax Margin

    n/a
    		 -339.1%

    Profit Margin

    n/a
    		 -339.1%

    EBITDA Margin

    n/a
    		 -275.94%

    EBIT Margin

    n/a
    		 -327.23%

    FCF Margin

    n/a
    		 -234.85%

    Dividends & Yields

    CBAY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -4.2%

    FCF Yield

    n/a
    		 -2.91%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for CBAY.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 12.9

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist